What con­tro­ver­sy? Eli Lil­ly plots Alzheimer's BLA fil­ing lat­er this year as FDA taps more an­ti-amy­loid drugs as break­throughs

The FDA is keep­ing the good news com­ing for Alzheimer’s drug de­vel­op­ers. And Eli Lil­ly is tak­ing them up on it.

Amid con­tin­ued con­tro­ver­sy around whether Bio­gen’s new flag­ship drug, Aduhelm, should have been ap­proved at all — and swelling, heat­ed de­bates sur­round­ing its $56,000 price tag — the agency had no is­sue hand­ing them and their Japan­ese part­ner Ei­sai a break­through ther­a­py des­ig­na­tion for a sec­ond an­ti-amy­loid be­ta an­ti­body, lecanemab, late Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER